

Edgar Filing: BIOTRANSPLANT INC - Form 8-K

BIOTRANSPLANT INC
Form 8-K
February 23, 2001

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 21, 2001

BIOTRANSPLANT INCORPORATED

(Exact name of registrant as specified in its charter)

DELAWARE	000-28324	04-3119555
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

Building 75, Third Avenue Charlestown Navy Yard Charlestown, MA	02129
-----	-----
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (617) 241-5200

N/A

(Former name or former address, if changed since last report)

Item 5. Other Events.

On February 21, 2001, Dr. Elliot Lebowitz, President and Chief Executive Officer of BioTransplant Incorporated, made a slide presentation at the BIO-CEO and Investor Conference relating to BioTransplant's business and its proposed merger with Eligix, Inc. and BioTransplant webcast the presentation. See the transcript of the webcast attached hereto as Exhibit 99.1.

Edgar Filing: BIOTRANSPLANT INC - Form 8-K

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

See Exhibit Index attached hereto.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 21, 2001

BIOTRANSPLANT INCORPORATED

By: /s/ Richard V. Capasso

Richard V. Capasso

Vice President, Finance and Treasurer

3

EXHIBIT INDEX

EXHIBIT NO.

EXHIBIT

Exhibit 99.1

Transcript of the Company's webcast held
on February 21, 2001

4